Bi-specific antibodies have proven effective in cancer treatment, while oligonucleotide therapeutics antibodies have the potential to address a variety of genetic and infectious diseases.
Whether or not they draw upon the power of personalized medicine, biopharmaceuticals are changing the face of drug development today. Select Science presents bi-specific antibodies and oligonucleotide therapeutics as just two among significant biopharmaceuticals poised to make headlines in 2024. Bi-specific antibodies have proven effective in cancer treatment, while oligonucleotide therapeutics antibodies have the potential to address a variety of genetic and infectious diseases.